Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertumaxomab in hormone refractory advanced breast cancer
NCT00351858Phase 2Terminated
- Sponsor
- Neovii Pharmaceuticals
- Start
- Jul 2006
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ertumaxomab in breast cancer, sponsored by Neovii Pharmaceuticals. Started Jul 2006; status: terminated.
02
Drugs
ertumaxomab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00351858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00351858.